Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. reports company developments for a commercial-stage medical technology and healthcare business centered on neurohealth therapies. Its recurring updates cover the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation platform cleared by the U.S. Food and Drug Administration for adults with major depressive disorder, adjunctive use in obsessive-compulsive disorder, anxious depression symptoms in adults with MDD, and first-line adjunctive treatment of MDD in adolescent patients aged 15-21.
News about STIM also covers operating results, U.S. and international system revenue, clinic services added through the completed Greenbrook acquisition, SPRAVATO-related clinic activity, executive and board changes, inducement equity awards, shareholder engagement, and cost-structure actions.
Neuronetics (NASDAQ: STIM) will release its fourth quarter 2025 financial and operating results before market open on Tuesday, March 17, 2026.
The company will host a live conference call at 8:30 a.m. Eastern Time the same day, available via webcast in listen-only mode; telephone registration is optional but recommended 10 minutes early.
Neuronetics (NASDAQ: STIM) reported selected preliminary unaudited results for Q4 and full-year 2025, showing Q4 revenue $41.8M (+86% as reported, +23% adjusted pro forma) and FY2025 revenue $149.2M (+99% as reported, +15% adjusted pro forma).
The company delivered positive operating cash flow $0.9M in Q4, shipped 49 NeuroStar Advanced Therapy systems in the quarter, and ended 2025 with $34.1M in total cash. Results assume the Greenbrook acquisition occurred January 1, 2024 with specified pro-forma adjustments.
Neuronetics (NASDAQ: STIM) said its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025 at 12:30 p.m. ET.
The presentation will be available via the conference portal to registered attendees.
Neuronetics (NASDAQ: STIM) announced that TriWest, the TRICARE regional administrator, updated its medical policy effective Nov 12, 2025 to cover NeuroStar TMS for adolescents aged 15 and older. The change applies immediately to TRICARE beneficiaries in 26 states, expanding access to a non‑drug, FDA‑cleared adolescent TMS option.
The release notes NeuroStar received FDA clearance for adolescents in 2024, cites an estimated 4.3 million U.S. adolescents aged 15–21 affected by major depression, and lists several private insurers that already cover NeuroStar.
Neuronetics (NASDAQ: STIM) reported Q3 2025 revenue of $37.3M, up 11% adjusted pro forma versus Q3 2024 and up 101% on an unadjusted basis, driven largely by the Greenbrook acquisition. U.S. Greenbrook clinic revenue was $21.8M (adjusted pro forma +25%). Gross margin declined to 45.9% from 75.6% year-over-year, reflecting clinic mix. Net loss was $(9.4)M (EPS $(0.13)). Cash totaled $34.5M at quarter end and cash used in operations improved to $0.8M in Q3. The company secured an additional $10M debt tranche from Perceptive and raised $7.8M net via an ATM offering. CEO Keith J. Sullivan plans to retire effective June 30, 2026 with a successor search underway.
Full-year 2025 revenue guidance was updated to $147M–$150M and Q4 revenue is expected at $40M–$43M.
Neuronetics (NASDAQ: STIM) granted inducement restricted stock units to twelve new employees on Oct 31, 2025 under Nasdaq Listing Rule 5635(c)(4), approved by its Compensation Committee and issued under the Company’s 2020 Inducement Incentive Plan.
The awards vest subject to continued service and include individual grants of 1,500 RSUs (seven recipients), 4,500 RSUs (two recipients), 11,250 RSUs (one recipient), 7,500 RSUs (one recipient), and 600 RSUs (one recipient), totaling 38,850 RSUs across twelve employees with multi‑year vesting schedules.
Neuronetics (NASDAQ: STIM) entered an exclusive three-year agreement with Elite DNA Behavioral Health to be the sole provider of transcranial magnetic stimulation (TMS) devices across Elite DNA’s 30+ locations. The collaboration also uses Neuronetics’ Greenbrook platform to deliver expanded fee-based operational and patient-support services, including PHQ-10 processing, TMS consultations, and scheduling. A pilot launched in Q4 2025 with plans to scale in 2026. The partnership is framed as a scalable, systemized model to expand NeuroStar access and streamline administrative operations for Elite DNA clinics.
Neuronetics (NASDAQ: STIM) will release its third quarter 2025 financial and operating results before market open on Tuesday, November 4, 2025.
The company will host a live conference call and webcast to review results at 8:30 a.m. Eastern Time the same day. The webcast will be available in listen-only mode at https://edge.media-server.com/mmc/p/yxrs8osc. Telephone participation requires registration; joining 10 minutes early is recommended.
Neuronetics (NASDAQ: STIM), maker of NeuroStar® Advanced Therapy, announced that New York State Medicaid will expand coverage for Transcranial Magnetic Stimulation (TMS) therapy to treat major depressive disorder (MDD). The coverage will be effective October 1, 2025 for fee-for-service members and November 1, 2025 for Managed Care Plans.
This expansion will provide TMS access to over 5 million New York Medicaid members, including nearly 1 million fee-for-service beneficiaries and 4.4 million individuals with Managed Care Organizations. NeuroStar's non-drug, non-invasive treatment has demonstrated up to 83% response rate and 62% remission rate for MDD patients.
Neuronetics (NASDAQ: STIM), a commercial stage medical technology company, has announced inducement awards for six new employees under NASDAQ Listing Rule 5635(c)(4). The awards consist of restricted stock units (RSUs) ranging from 1,200 to 18,750 units per employee, with specific vesting schedules over 3-4 years.
The company specializes in neuroscience treatments, notably the NeuroStar Advanced Therapy System, which has delivered over 7.4 million treatments for major depressive disorder (MDD). Through Greenbrook TMS centers, Neuronetics has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.